FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. CTKB, a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
UBS Precision Medicine Summit in Dana Point, CA
Panel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern TimeWells Fargo Healthcare Conference in Boston, MA
Participating in investor 1×1 meetings on Thursday, September 4, 2025Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY
Fireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time
Interested parties may access live and archived webcasts of the presentations for the UBS and Morgan Stanley events referenced above on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences CTKB is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at http://www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Stephanie Olsen
Lages & Associates
(949) 453-8080
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
CTKBCytek Biosciences Inc$4.036.33%Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Reveal Full ScoreEdge RankingsMomentum15.82Growth29.10QualityN/AValue70.79Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs
